Construct: ORF ccsbBroad304_12194
Construct Description:
- Construct Type:
- ORF
- Other Identifiers:
- ORF005331.1_s304c1, BRDN0000405222
- Derived from:
- ccsbBroadEn_12194
- DNA Barcode:
- None
- Epitope Tag:
- V5
- Notes:
- No stop codon in insert
Originally Annotated References:
- Gene:
- CASC1 (55259)
Vector Information:
- Vector Backbone:
- pLX_304
- Pol II Cassette 1:
- PGK-BlastR
- Pol II Cassette 2:
- CMV-ccsbBroad304_12194
- Selection Marker:
- BlastR
- Visible Reporter:
- n/a
- Epitope Tag:
- V5
Current transcripts matched by this ORF:
| Taxon | Gene | Symbol | Description | Transcript | Nuc. Match %[?]A simple nucleotide-based global alignment percentage, calculated as follows: total nt. matches ---------------------------------- aligned length (incl. gaps) |
Prot. Match %[?]A simple amino acid-based global alignment percentage, calculated as follows: total aa. matches ---------------------------------- aligned length (incl. gaps) |
Match Diffs[?]This field may contain sequence annotations in HGVS format. For more information about HGVS annotations, please refer to the HGVS Quick Reference Guide. | |
|---|---|---|---|---|---|---|---|---|
| 1 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001204102.3 | 99.9% | 99.8% | 1778C>A |
| 2 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001319978.2 | 99.9% | 99.8% | 1778C>A |
| 3 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001352061.2 | 99.9% | 99.8% | 1778C>A |
| 4 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001204101.3 | 97% | 96.8% | 0_1ins57;2_3delTGinsAA;1721C>A |
| 5 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001082973.3 | 94.3% | 94.2% | 1_120del;1898C>A |
| 6 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_018272.5 | 93.5% | 93.4% | 1_138del;1916C>A |
| 7 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001352065.2 | 89.2% | 89.2% | 0_1ins216;1562C>A |
| 8 | human | 55259 | CASC1 | cancer susceptibility 1 | XM_005253408.1 | 89.2% | 89.2% | 0_1ins216;1562C>A |
| 9 | human | 55259 | CASC1 | cancer susceptibility 1 | XM_017019560.1 | 87.2% | 87.2% | 1_294del;2072C>A |
| 10 | human | 55259 | CASC1 | cancer susceptibility 1 | XM_005253406.1 | 86.6% | 86.5% | 1_312del;2090C>A |
| 11 | human | 55259 | CASC1 | cancer susceptibility 1 | XM_011520723.1 | 86.6% | 86.5% | 1_312del;2090C>A |
| 12 | human | 55259 | CASC1 | cancer susceptibility 1 | XM_024449031.1 | 86.5% | 86.5% | 1756_1757delTGinsGT;1758_1759ins270 |
| 13 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001352066.2 | 84.2% | 84.1% | 938_939ins318;1460C>A |
| 14 | human | 55259 | CASC1 | cancer susceptibility 1 | NR_147911.2 | 83% | (many diffs) | |
| 15 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001352062.2 | 81.7% | 81.7% | 1_120del;1876_1877delTGinsGT;1878_1879ins270 |
| 16 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001352067.2 | 81.3% | 81.2% | (many diffs) |
| 17 | human | 55259 | CASC1 | cancer susceptibility 1 | NR_147909.2 | 80.7% | (many diffs) | |
| 18 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001352064.2 | 79.5% | 79.4% | 1_120del;1058_1059ins318;1580C>A |
| 19 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001352063.2 | 78.9% | 78.8% | 1_138del;1076_1077ins318;1598C>A |
| 20 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001319977.2 | 75.9% | 75.8% | 0_1ins216;1540_1541delTGinsGT;1542_1543ins270 |
| 21 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001082972.3 | 75% | 75% | 1_312del;2068_2069delTGinsGT;2070_2071ins270 |
| 22 | human | 55259 | CASC1 | cancer susceptibility 1 | XR_001748797.1 | 74.9% | (many diffs) | |
| 23 | human | 55259 | CASC1 | cancer susceptibility 1 | XM_006719101.1 | 73% | 72.9% | 1_312del;1250_1251ins318;1772C>A |
| 24 | human | 55259 | CASC1 | cancer susceptibility 1 | NM_001352068.2 | 70.9% | 70.8% | 938_939ins318;1438_1439delTGinsGT;1440_1441ins270 |
| 25 | human | 55259 | CASC1 | cancer susceptibility 1 | XM_017019565.1 | 61.4% | 61.4% | (many diffs) |
| 26 | human | 55259 | CASC1 | cancer susceptibility 1 | NR_147910.2 | 56% | (many diffs) | |
| 27 | human | 55259 | CASC1 | cancer susceptibility 1 | XM_011520726.1 | 55.4% | 53.1% | (many diffs) |
| 28 | human | 55259 | CASC1 | cancer susceptibility 1 | XM_011520727.1 | 53.2% | 53.2% | 1_312del;1557_1558ins783 |
Sequence Information
Note: uppercase bases indicate empirically verified sequence.
- ORF start:
- 69
- ORF end:
- 2097
- ORF length:
- 2028
- Sequence:
-
1 ggtctatata agcagagctc tctggctaac tgtcgggatc aacaagtttg tacaaaaaag 61 ttggcaccat ggaaaggctt gaaatacagc gaattgagaa agaaaaatgg catcgacttg 121 aagcaaaaga tctagaaagg agaaatgaag aacttgaaga actttattta ttagagaggt 181 gttttcctga agcagagaaa ttgaaacagg aaactaaatt gctttctcag tggaagcact 241 acattcaatg tgatgggagt cctgatcctt cagtagccca agaaatgaac acgtttatta 301 gtttgtggaa agagaaaaca aatgagactt ttgaggaagt gattgagaag agtaaagtag 361 tgctaaattt aattgagaaa ttgaaattta ttttactgga aactccacca tgtgatttgc 421 aagataaaaa tataatacag taccaagaat caatactaca actgcaggag ctccttcatc 481 ttaaattcgg tgtagccaca gaaatacttc tcaaacaagc tagtactttg gcagatctgg 541 acagtggaaa tatggaaaaa gtcattaaag atgaaaatgt tactctgtat gtgtgggcaa 601 acctcaagaa gaatccaagg cacagaagtg ttagattctc tgaaacacaa attggatttg 661 agattccaag gatattagca acaagtgaca ttgctgtacg actcctgcat acccactatg 721 atcatgtttc tgcactgcac cctgtttcaa caccatcaaa agaatacact tctgcagtaa 781 ctgagcttgt caaagatgat gttaagaatg tagaaaaagc aatcagcaag gaggtcgaag 841 aagagtccaa acaacaagaa agagggtctc acttaattca ggaggaagaa ataaaagttg 901 aggaggaaca aggtgatatt gaagtgaaaa tgagttctgc tgaggaagaa tctgaagcca 961 taaaatgtga acgagagatg aaagtattaa gtgaaactgt ttcagcagca cagttgttgc 1021 tggtagagaa ttcttctgaa aagccagatt tctttgaaga caatgtggtg gatttatgcc 1081 agttcacaac tctgggtgga gtataccact tggatatttt ggagcttcct ccacagtgta 1141 aaccagtgaa gggatggatg attgtggaaa tactcaaaga aggattacag aaatacacat 1201 atcctccgga aactacagaa gagtttgaga cagaaaatgc tttcccacct atagaggtca 1261 cacttgaggt tcatgagaat gtaatctttt ttgaggatcc tgtggttgta aggtgggatg 1321 ctgaaggtaa acattggaga actgatggca tcagcaatgt atcctacaaa ccaaaagaaa 1381 gacttgtaac attcagcctg gacacctttg gccctgttac cttgattcaa gatgctcata 1441 ttaacatgcc gtaccagtca tgggaactaa gaccacttga tgtaaataaa gtacttttaa 1501 ctgtgactac agtatttact gagattcaaa tacaaattaa ggaaaacctc tgcatgttat 1561 cttcaatcaa actaaaagac aagaaacaca tctctatttt ggaaggaacc tggatgactc 1621 ctattccttt cattattgct ttgaaagaag ctggactgaa tatctttcct actagacact 1681 ctcattttta tgttattata aacaataagg ttcctttggt agaagtgaaa gcttatcgac 1741 agatggccct actaagttct gcttttgcat ttggttggag caagtggaac ctactatgta 1801 attctacaaa agtcgtattt aaggtgaggg aacaccttac tgaagaatgt actgagaatc 1861 ctaattgggc ccttttaatg tttagtggtg acagagcaca aagactgaag atcaaggaag 1921 agagtgaggc attttctgaa gcacttaaag aagaaactga gtttcattct actttatatc 1981 acatggtgaa ggattttgct tctgaggaag caatggagaa agtcaggagt tccaactgtc 2041 agtttgtcaa ctctgtgtgc cacatgctgc tctctaccag attgctcagc tactccttgc 2101 caactttctt gtacaaagtg gttggtaagc ctatccctaa ccctctcctc ggtctcgatt 2161 ctacgtagta atgagctagc gctaaccggt ggcgcgttaa gtcgacaatc aacctctgga 2221 tta